Dr. Vogelzang on XL184's Effect on Bone Metastases

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada on cabozantinib's (XL184) effect on bone metastases.

Dr. Vogelzang says some cancers are more likely than others to spread to the bone. Prostate cancer is the premier example of this, with over 90% of patients having bone metastases. Melanoma, lung cancer and breast cancer have lower but consistent rates of bone metastases. With cabozantinib, somewhere between 60% and 90% of the patients had improvement in the bone scan, improvement in bone pain, improvement in reduced pain and reduction in need for pain medicine.